Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 11/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 1.00 |
| ▸ | LMNA | P02545 | 8/20 | 1.00 |
| ▸ | HPGD | P15428 | 4/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 7/20 | 0.82 |
| ▸ | MAPT | P10636 | 7/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.68 |
| ▸ | GAA | P10253 | 1/20 | 0.68 |
| ▸ | PTGES | O14684 | 1/20 | 0.67 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 3/20 | 0.52 |
| ▸ | PARP1 | P09874 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | MPI | P34949 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4022842 | 0.81 | KDM4E (1.00) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| SCHEMBL31721163 | 0.81 | LMNA (1.00) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| SCHEMBL15264704 | 0.81 | KDM4E (0.68) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| SCHEMBL2360729 | 0.81 | LMNA (1.00) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| SCHEMBL6070964 | 0.81 | KDM4E (0.68) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| SCHEMBL4234216 | 0.81 | KDM4E (0.68) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| SCHEMBL15827841 | 0.81 | KDM4E (0.68) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| SCHEMBL6643889 | 0.81 | ALDH1A1 (0.68) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| SCHEMBL15472018 | 0.81 | KDM4E (0.84) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| SCHEMBL13949522 | 0.81 | KDM4E (0.68) | KDM4EALDH1A1LMNAHPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023088388-A1 | TETRAHYDROCARBAZOLE COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | 杭州拿因生物科技有限责任公司 | 2023-05-25 | — | — | WO | disclosed |
| CN-110914270-B | Preparation method of pirlindole enantiomer and salt thereof | 社会医疗技术员技术股份公司 | 2022-05-03 | — | — | CN | disclosed |
| CN-110831943-B | Method for producing piperazine rings for the synthesis of pyrazinocarbazole derivatives | 社会医疗技术员技术股份公司 | 2022-05-03 | — | — | CN | disclosed |
| EP-3612534-B1 | PROCESS FOR THE PREPARATION OF PIPERAZINE RING FOR THE SYNTHESIS OF PYRAZINOCARBAZOLE DERIVATIVES | TECNIMEDE SOCIEDADE TECNICO MEDICINAL SA (PT) | 2021-12-22 | — | — | EP | disclosed |
| EP-3612534-B1 | PROCESS FOR THE PREPARATION OF PIPERAZINE RING FOR THE SYNTHESIS OF PYRAZINOCARBAZOLE DERIVATIVES | TECNIMEDE SOCIEDADE TECNICO MEDICINAL SA (PT) | 2021-12-22 | — | — | EP | disclosed |
| US-11008328-B2 | Processes for the preparation of pharmaceutically acceptable salts of (R)-Pirlindole and (S)-Pirlindole | TECNIMEDE, SOCIEDADE TÉCNICO-MEDICINAL, SA (PT) | 2021-05-18 | — | — | US | disclosed |
| US-11008328-B2 | Processes for the preparation of pharmaceutically acceptable salts of (R)-Pirlindole and (S)-Pirlindole | TECNIMEDE, SOCIEDADE TÉCNICO-MEDICINAL, SA (PT) | 2021-05-18 | — | — | US | disclosed |
| US-11008327-B2 | Processes for the preparation of pharmaceutically acceptable salts of (R)-Pirlindole and (S)-Pirlindole | TECNIMEDE, SOCIEDADE TÉCNICO-MEDICINAL, SA (PT) | 2021-05-18 | — | — | US | disclosed |
| US-11008327-B2 | Processes for the preparation of pharmaceutically acceptable salts of (R)-Pirlindole and (S)-Pirlindole | TECNIMEDE, SOCIEDADE TÉCNICO-MEDICINAL, SA (PT) | 2021-05-18 | — | — | US | disclosed |
| US-20200190098-A1 | PROCESS FOR THE PREPARATION OF PIRLINDOLE ENANTIOMERS AND ITS SALTS | TECNIMEDE, SOCIEDADE TÉCNICO-MEDICINAL, SA (PT) | 2020-06-18 | — | — | US | disclosed |
| WO-2004110999-A1 | TETRAHYDROCARBAZOLE DERIVATIVES AND THEIR PHARMACEUTICAL USE | SMITHKLINE BEECHAM CORPORATION (US) | 2004-12-23 | — | — | WO | disclosed |
| EP-1044976-B1 | Process for the preparation of pirlindole hydrochloride | ERREGIERRE SPA (IT) | 2002-07-24 | — | — | EP | disclosed |
| EP-1044976-A1 | Process for the preparation of pirlindole hydrochloride | ERREGIERRE S.p.A. (IT) | 2000-10-18 | — | — | EP | disclosed |
| EP-0095067-B1 | PROCESS FOR THE PREPARATION OF OPTIONALLY SUBSTITUTED 1,2,3,4-TETRAHYDRO-9-CYANOMETHYL-CARBAZOL-1-ONES | CASSELLA Aktiengesellschaft (DE) | 1986-11-12 | — | — | EP | disclosed |
| US-4485240-A | Process for the preparation of optionally-substituted 1,2,3,4-tetrahydro-9-cyanomethylcarbazol-1-ones | CASSELLA AKTIENGESELLSCHAFT (DE) | 1984-11-27 | — | — | US | disclosed |
| EP-0095067-A2 | Process for the preparation of optionally substituted 1,2,3,4-tetrahydro-9-cyanomethyl-carbazol-1-ones | CASSELLA Aktiengesellschaft (DE) | 1983-11-30 | — | — | EP | disclosed |
| EP-0028270-B1 | PYRAZINO-CARBAZOLES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | CASSELLA Aktiengesellschaft (DE) | 1983-02-16 | — | — | EP | disclosed |
| US-4271073-A | ANTIDEPRESSANTS | CASSELLA AKTIENGESELLSCHAFT (DE) | 1981-06-02 | — | — | US | disclosed |
| EP-0028270-A1 | Pyrazino-carbazoles, process for their preparation and pharmaceutical compositions containing them | CASSELLA Aktiengesellschaft (DE) | 1981-05-13 | — | — | EP | disclosed |
| US-4258043-A | ANTIDEPRESSANTS | CASSELLA AKTIENGESELLSCHAFT (DE) | 1981-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200190098-A1 | PROCESS FOR THE PREPARATION OF PIRLINDOLE ENANTIOMERS AND ITS SALTS | PIR, DRD1, DRD4 | KDM4E 1281/4885ALDH1A1 1112/4885LMNA 3550/4885 |
| US-11008327-B2 | Processes for the preparation of pharmaceutically acceptable salts of (R)-Pirlindole and (S)-Pirlindole | PIR, DRD5, DRD1 | KDM4E 2468/4885ALDH1A1 1285/4885LMNA 3161/4885 |
| US-11008328-B2 | Processes for the preparation of pharmaceutically acceptable salts of (R)-Pirlindole and (S)-Pirlindole | PIR, DRD1, DRD5 | KDM4E 3430/4885ALDH1A1 1528/4885LMNA 4033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.